Vanda's strong financials and product lineup show promise, but management concerns and FDA disputes may hinder growth. Learn ...

Highlights,Vanda Pharmaceuticals posts improved earnings, surpassing market expectations.,Company executives increase stock ...

Vanda Pharmaceuticals (VNDA) announced that a New Drug Application was submitted to the U.S. FDA requesting marketing approval of Bysanti for ...

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) requesting marketing approval of ...

WASHINGTON - Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), currently valued at $273.5 million, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Bysanti ...

Blue-chip tech stocks are a big part of President Donald Trump's portfolio, according to his latest financial disclosures.

Bank of New York Mellon Corp lessened its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) by 14.7% in the 4th quarter, according to its most recent filing with the SEC.

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...